Moderate

Secondary hypertension — endocrine and renovascular screening

secondary HTN · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Targeted evaluation for identifiable causes of hypertension, especially primary aldosteronism, renovascular disease, renal parenchymal disease, phaeochromocytoma and Cushing syndrome. Indicated in resistant, young-onset, severe or features-suggestive hypertension to enable curative or specific therapy.

Red flags

  • Malignant hypertension with end-organ damage
  • Flash pulmonary oedema (bilateral renal artery stenosis)
  • Paroxysmal headache/palpitations/sweating (phaeochromocytoma)
  • AKI after starting ACEi/ARB (renovascular)
  • Severe spontaneous or diuretic-induced hypokalaemia (aldosteronism)

Assessment

Differential diagnosis

  • Primary aldosteronism
  • Renovascular hypertension (atherosclerotic or fibromuscular)
  • Renal parenchymal disease (CKD)
  • Phaeochromocytoma/paraganglioma
  • Cushing syndrome
  • Obstructive sleep apnoea / thyroid / coarctation

Investigations

  • Aldosterone:renin ratio (primary aldosteronism) — withhold interfering drugs where possible
  • U&E (hypokalaemia), eGFR, urine ACR, urinalysis
  • Renal duplex ultrasound / CT or MR angiography (renovascular)
  • Plasma/urine metanephrines (phaeochromocytoma)
  • Overnight dexamethasone suppression / late-night salivary cortisol (Cushing)
  • TFTs, sleep study if OSA suspected

Management

  • Identify who to screen: resistant hypertension, young onset (<40), severe/malignant, hypokalaemia, incidental adrenal mass or suggestive features
  • Confirm sustained hypertension with out-of-office readings and review adherence/drug causes
  • Measure aldosterone:renin ratio for primary aldosteronism (the commonest secondary cause), accounting for interfering antihypertensives
  • If ARR positive, arrange confirmatory testing and adrenal CT +/- adrenal vein sampling via endocrinology
  • Screen for renovascular disease with renal duplex or CT/MR angiography when clinical clues exist (flash pulmonary oedema, bruit, AKI on ACEi, FMD in young women)
  • Exclude renal parenchymal disease with renal function, urinalysis, ACR and ultrasound
  • Test for phaeochromocytoma (metanephrines) if paroxysmal symptoms, labile BP or adrenal mass
  • Screen for Cushing syndrome if cushingoid features or resistant hypertension with diabetes
  • Consider OSA, thyroid disease and coarctation per clinical picture
  • Treat the specific cause: MRA or adrenalectomy for aldosteronism, revascularisation selectively for renovascular disease, surgery for phaeochromocytoma/Cushing
  • Optimise BP control pending definitive treatment
  • Refer to the relevant specialist (endocrinology, vascular, nephrology) for confirmatory testing and management

Drugs & doses

Spironolactone 25-50 mg PO daily OR eplerenone 25-50 mg PO twice daily (primary aldosteronism medical therapy)
Amlodipine 5-10 mg PO daily and other agents to control BP during work-up
Phenoxybenzamine 10 mg PO twice daily, uptitrated (alpha-blockade before phaeochromocytoma surgery)
Doxazosin MR 4-8 mg PO daily (add-on BP control)

Disposition

Outpatient work-up with endocrinology/hypertension specialist; vascular or nephrology referral for renovascular disease. Surgery for phaeochromocytoma, Cushing or aldosterone-producing adenoma.

Complications & pitfalls

  • Cardiovascular and renal damage from uncontrolled hypertension
  • Hypertensive crisis in undiagnosed phaeochromocytoma
  • Progressive renovascular ischaemic nephropathy
  • Hypokalaemia from aldosteronism
  • Missed curable cause

Exam pearls

  • Primary aldosteronism is far more common than historically thought — screen liberally in resistant/hypokalaemic HTN
  • Do not start alpha-blockade without beta cover timing in phaeochromocytoma, and never beta-block first (unopposed alpha)
  • AKI on starting an ACE inhibitor suggests bilateral renal artery stenosis
  • Fibromuscular dysplasia causes renovascular HTN in young women and is treatable by angioplasty
  • Account for interfering drugs when interpreting the aldosterone:renin ratio

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.